Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
about
From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemiaArsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathwayMurine models to evaluate novel and conventional therapeutic strategies for cancerRetinoic acid and arsenic for treating acute promyelocytic leukemiaThe cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodiesHow animal models of leukaemias have already benefited patientsOne mouse, one patient paradigm: New avatars of personalized cancer therapyTargeting of leukemia-initiating cells in acute promyelocytic leukemiaRetinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteinsArsenic trioxide induces apoptosis in human platelets via C-Jun NH2-terminal kinase activationNitric oxide and calcium ions in apoptotic esophageal carcinoma cells induced by arsenite.In vivo activation of cAMP signaling induces growth arrest and differentiation in acute promyelocytic leukemia.BCL-2 cooperates with promyelocytic leukemia retinoic acid receptor alpha chimeric protein (PMLRARalpha) to block neutrophil differentiation and initiate acute leukemia.Curing all patients with acute promyelocytic leukemia: are we there yet?Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Acute promyelocytic leukemia: from treatment to genetics and back.In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications.Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.Arsenic trioxide inhibits nuclear receptor function via SEK1/JNK-mediated RXRalpha phosphorylation.Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Targeted therapies for the myeloid leukaemias.Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL.In vivo analysis of the molecular genetics of acute promyelocytic leukemia.APL, a model disease for cancer therapies?Arsenic trioxide, a therapeutic agent for APL.Biological features of primary APL blasts: their relevance to the understanding of granulopoiesis, leukemogenesis and patient management.Orchestration of multiple arrays of signal cross-talk and combinatorial interactions for maturation and cell death: another vision of t(15;17) preleukemic blast and APL-cell maturation.The theory of APL.Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission.All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemiaThe PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.PML targeting eradicates quiescent leukaemia-initiating cells.Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxideIn vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancerCombining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia.Cooperation of cytokine signaling with chimeric transcription factors in leukemogenesis: PML-retinoic acid receptor alpha blocks growth factor-mediated differentiation.The APL paradigm and the "co-clinical trial" project.Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide
P2860
Q24605527-3C5DC6BE-C98B-4854-A75B-E35ABB5FD2C5Q24623800-6C16411D-407F-4216-9B9E-F44F24279043Q24673595-230FD83C-E71B-45D9-9A99-57812483421EQ24809165-6F74DA5A-9721-4CC5-8B7E-61DF77AB510DQ26853348-38A04204-B4F0-47DD-9B1F-C0DE271C784AQ26997702-D3F7A4F9-17AB-438A-AF08-07FC6A3BA15BQ27023342-F0D2C086-4851-4520-A38F-8C8CAE0D0B54Q28083807-AFB9413E-678A-4674-86E0-624813AF5D35Q28344657-90E5EE21-3D01-4690-8C02-CDFD81970DFAQ28539034-968564FA-61F1-4253-B4FA-3E048D48AC93Q30724199-7873C1E9-D164-4E19-8719-A262BE6041BAQ33185196-5BBBB007-6E59-4792-8A65-F88CD3DA0ED6Q33335885-D3305E05-9A1F-4644-853C-17C307879E72Q33613426-02E8CEA1-CA80-4649-B6E7-0E0AA8F802F4Q33631350-57512E21-2FF9-44B3-A68E-CEFA2474C403Q33739256-043DA2A0-D1A3-4B94-94EB-63D61BA7592DQ33739259-4E93E384-231D-4AB6-BD3B-A188244AE5F8Q33929824-051D0F61-6855-4A38-AFA4-18B98BBF27B3Q34014502-EFDF392B-8F21-4CBD-94E3-C2357B18FCF0Q34035750-DD110CD4-E91D-4B2D-A314-9BCBC21966B9Q34046794-378BD9D2-BA64-4C26-B774-2932C457CFF1Q34074884-E58F642A-297C-4968-A457-764B96496545Q34254302-68B583BC-D83F-4E3B-91A8-85CBB01E5EDEQ34405484-A7F0C059-854F-4F8E-B986-A71DD2EE580BQ34435486-C20A4B1C-AB19-4BB6-8018-7F7B207E18CAQ34435492-945180F6-03A3-42FC-904B-28BB5E999AA8Q34435497-F1D96214-EBF9-46DA-8F4A-A949032242EFQ34435506-20C655F1-07D6-4F55-B3C4-66DDB823EDFBQ34435538-3BEBD613-6A8E-4AEE-9477-25CE7CAFCAC1Q34435558-9EF400A7-1BD8-4B33-8794-D05EF6047795Q34546653-AFE796A7-77B6-4674-8329-D1074AFEC96FQ34548159-B91CE602-328B-4440-8B2D-DC4755B32642Q34575618-7A0238E7-B407-4822-86A9-9E1BE416E034Q34591761-D5DEEBDD-3CFD-48A5-B6DC-6BD7A960936AQ34609485-7591CA82-DE1F-4E05-8F2A-A465C39A7E4EQ34667419-496FAC29-81FF-4BF0-8365-E78A1C5A372AQ35018971-31059216-255D-4243-A4D1-F069CB27E461Q35150597-694D7BB3-A4E2-44BA-93D3-822817C942E2Q35568084-C189FC4E-C400-4AD6-A831-12B70A4AB126Q35949253-111AFEE3-B597-4577-B35F-BAF9A52374F4
P2860
Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia
description
1999 nî lūn-bûn
@nan
1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@ast
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@en
type
label
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@ast
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@en
prefLabel
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@ast
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@en
P2093
P2860
P356
P1476
Retinoic acid and arsenic syne ...... f acute promyelocytic leukemia
@en
P2093
Guillemin MC
Lallemand-Breitenbach V
P2860
P304
P356
10.1084/JEM.189.7.1043
P407
P577
1999-04-01T00:00:00Z